EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma

Fabian Artusa, Sven Lamatsch, Minh Duc Phan, Burcin Özdirik, Hilmar Berger, Mara Egerer, Jana Knorr-Klocke, Janett Fischer iD, Rhea Veelken, Florian van Bömmel, Thomas Berg iD, Kai Kappert und 6 weitere

Liver International · 2025

DOI: 10.1111/liv.70121 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Fabian Artusa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Be…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Receptors, Urokinase Plasminogen Activator, Liver Cirrhosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The introduction of immune checkpoint inhibitor (ICI) based therapies has significantly improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the variable treatment response and the uncertain benefit in patients with advanced liver cirrhosis emphasise the urgent need for prognostic and predictive biomarkers guiding patient selection. The soluble urokinase plasminogen activator receptor (suPAR) is strongly associated with inflammation, liver cirrhosis and various types of cancer. In this study, we investigated suPAR as a potential novel biomarker in patients with unresectable HCC.

Methods

This multicenter retrospective study, conducted at three German tertiary care centers, included 90 patients with unresectable HCC and suPAR measurements prior to and during atezolizumab/bevacizumab therapy. Patients with liver cirrhosis without HCC ( n = 235) and non‐cirrhotic patients with other gastrointestinal tumours ( n = 155) were selected as control cohorts.

Results

Median suPAR levels were significantly higher in patients with liver cirrhosis compared to non‐cirrhotic cancer patients. A strong association with parameters of liver function, but not with HCC characteristics, was observed. In patients with HCC receiving atezolizumab/bevacizumab, suPAR was the most accurate independent predictor of hepatic decompensation and overall survival (OS). In addition, suPAR was able to stratify the risk of hepatic decompensation within the different Child‐Pugh classes.

Conclusions

SuPAR represents a promising novel biomarker in patients with HCC treated with ICI‐based therapies and bears the potential to guide the selection of antitumoral systemic therapies in patients with advanced liver cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsReceptors, Urokinase Plasminogen ActivatorLiver CirrhosisHumansMaleFemaleRetrospective StudiesMiddle AgedAgedBevacizumabAntibodies, Monoclonal, HumanizedGermanyPrognosisBiomarkers, TumorImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

atezolizumabbevacizumabbiomarkerhepatocellular carcinoma (HCC)soluble urokinase plasminogen activator receptor (suPAR)survival

Substanzen

Receptors, Urokinase Plasminogen ActivatorBevacizumabAntibodies, Monoclonal, HumanizedatezolizumabPLAUR protein, humanBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.
  • Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
  • Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.
  • Institute for Liver and Digestive Health, University College London, London, UK.

ORCID-Profile: Janett Fischer, Thomas Berg, Münevver Demir, Frank Tacke, Raphael Mohr

Zitieren

APA

Artusa, F., Lamatsch, S., Phan, M. D., Özdirik, B., Berger, H., Egerer, M., Knorr-Klocke, J., Fischer, J., Veelken, R., van Bömmel, F., Berg, T., Kappert, K., Tauber, R., Puengel, T., Engelmann, C., Demir, M., Tacke, F., & Mohr, R. (2025). Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma. Liver International. https://doi.org/10.1111/liv.70121

Vancouver

Artusa F, Lamatsch S, Phan MD, Özdirik B, Berger H, Egerer M, et al. Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma. Liver International. 2025. doi:10.1111/liv.70121

BibTeX
@article{Artusa2025,
  author = {Artusa, Fabian and Lamatsch, Sven and Phan, Minh Duc and Özdirik, Burcin and Berger, Hilmar and Egerer, Mara and Knorr-Klocke, Jana and Fischer, Janett and Veelken, Rhea and van Bömmel, Florian and Berg, Thomas and Kappert, Kai and Tauber, Rudolf and Puengel, Tobias and Engelmann, Cornelius and Demir, Münevver and Tacke, Frank and Mohr, Raphael},
  title = {Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70121}
}
Kostenlos starten →